Table2_Effects of exercise modalities on decreased blood pressure in patients with hypertension.docx by Thiago Rozales Ramis (5311217)

UNC-62 RNAi decreases expression of collagen genes and increases expression of intestinal genes. by Eric L. Van Nostrand (30730)

“…For 1699 genes with intestine-enriched expression <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003325#pgen.1003325-McGhee1" target="_blank">[23]</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003325#pgen.1003325-Pauli1" target="_blank">[33]</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003325#pgen.1003325-Spencer1" target="_blank">[34]</a> as well as the subset of 291 genes that also decrease expression with age <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003325#pgen.1003325-Budovskaya1" target="_blank">[10]</a>, we determined the average mean-centered fold-change from triplicate RNA-seq experiments of <i>unc-62</i> RNAi as compared to controls. …”

Muscle quality, but not muscle thickness, is decreased in different age groups of active older women by Pedro Lopez (4530202)

KCl treatment increases Elk1 SUMOylation and decreases katanin-p60 expression. by Ece Selçuk (436963)

Lipolytic treatment decreased cellular neutral lipids and increased extracellular fatty acids and glycerol. by Caroline Louis (332423)

“…Cellular neutral lipids (corresponding to µmol of fatty acids in cellular neutral lipids) were expressed per mg of total cell protein (A). A significant decrease of cellular lipid contents was noted throughout the lipolytic process for the conditions with PCB-28 (<i>p</i> = 0.005) and the cocktail of PCBs (<i>p</i> = 0.029). …”

Decreasing NR1 and NR2A gene expression in 5-, 14- and 21-day groups. by Chenxia Han (4020017)

ATG 5 down-regulation decreases human A53T ASYN-induced death in rat cortical neurons. by Maria Xilouri (264240)

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

Subjects: